Compare BAND & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BAND | KMDA |
|---|---|---|
| Founded | 2000 | 1990 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.6M | 488.6M |
| IPO Year | 2017 | 2013 |
| Metric | BAND | KMDA |
|---|---|---|
| Price | $20.42 | $8.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $20.40 | $14.00 |
| AVG Volume (30 Days) | ★ 359.0K | 55.5K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 2.96% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $204,113,000.00 | N/A |
| Revenue This Year | $15.16 | $13.94 |
| Revenue Next Year | $6.18 | $9.84 |
| P/E Ratio | ★ N/A | $24.59 |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $11.33 | $6.35 |
| 52 Week High | $19.59 | $9.35 |
| Indicator | BAND | KMDA |
|---|---|---|
| Relative Strength Index (RSI) | 71.36 | 42.53 |
| Support Level | $13.20 | $7.96 |
| Resistance Level | N/A | $8.40 |
| Average True Range (ATR) | 1.04 | 0.19 |
| MACD | 0.14 | 0.01 |
| Stochastic Oscillator | 97.77 | 41.25 |
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of the company's revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.